Read by QxMD icon Read

"Conjugated estrogen"

Narathorn Suwanvesh, Jittima Manonai, Areepan Sophonsritsuk, Wichai Cherdshewasart
OBJECTIVES: To compare the effects of a 12-week treatment with Pueraria mirifica (PM) gel or a conjugated estrogen cream on vaginal maturation index, vaginal symptom score, vaginal health assessment score, and vaginal flora in postmenopausal women. METHODS: In a prospective, noninferiority, randomized controlled study, 82 postmenopausal women with at least one vulvovaginal symptom, that is, dryness, soreness, irritation, dyspareunia, or discharge, were recruited...
October 3, 2016: Menopause: the Journal of the North American Menopause Society
David F Archer, Ellen W Freeman, Barry S Komm, Kelly A Ryan, Ching-Ray Yu, Sebastian Mirkin, JoAnn V Pinkerton
OBJECTIVES: Conjugated estrogens/bazedoxifene (CE/BZA) reduced menopause-related hot flashes (HFs) in the Selective estrogens, Menopause, And Response to Therapy (SMART) trials. This post hoc pooled analysis of SMART-1 and -2 further characterized effects of CE/BZA on HFs in the overall population and patient subgroups. METHODS: Data from two randomized, double-blind, placebo- and active-controlled, phase 3 studies were pooled for nonhysterectomized postmenopausal women with moderate/severe HFs given CE 0...
September 27, 2016: Journal of Women's Health
Ai-Jun Sun, Ya-Ping Wang, Bei Gu, Ting-Ping Zheng, Shou-Qing Lin, Wen-Pei Bai, Yang Wei, Shao-Fen Zhang, Ying Zhang
OBJECTIVE: To evaluate the efficacy and safety of Heyan Kuntai Capsule (, HYKT) and hormone therapy (HT) on perimenopausal syndromes (PMSs). METHODS: From 2005 to 2008, 390 women with PMSs were recruited from 4 clinic centers. The inclusion criteria included ages 40 to 60 years, estradiol (E2) below 30 ng/L, and follicle stimulating hormone (FSH) above 40 IU/L, etc. The patients were randomly assigned to HYKT group or HT group by random number table method, administrated HYKT or conjugated estrogen with/without medroxyprogesterone acetate tablets for 12 months...
September 20, 2016: Chinese Journal of Integrative Medicine
P Hadji, K A Ryan, C-R Yu, S Mirkin, Barry S Komm
OBJECTIVES: To evaluate the efficacy of conjugated estrogens/bazedoxifene (CE/BZA) on bone mineral density (BMD), bone turnover markers (BTM), and menopause-specific quality of life (MENQOL) in European women. METHODS: Data through 12 months were pooled from two double-blind, randomized, controlled trials in non-hysterectomized postmenopausal women who received CE/BZA or placebo. Women from European study sites with evaluable BMD (n = 60), BTM (n = 56), and MENQOL questionnaire (n = 236) data were included and compared with 1523 women from US study sites (n = 730 with evaluable data for bone outcomes)...
October 2016: Climacteric: the Journal of the International Menopause Society
W Xue, A J Sun, T P Zheng, J F Jiang, Y P Wang, Y Zhang, F L Chen, Y Deng, Y F Wang
OBJECTIVE: To explore the effects of five different therapy in women at early stage of menopause on menopausal symptoms, quality of Life and cardiovascular risk factors. METHODS: A total of 140 women at early stage of menopause were randomly divided into five groups. Thirty women took Conjugated estrogen and medroxyprogesterone acetate(CEE+ MPA) sequential therapy, 27 women took estradiol valerate and medroxyprogesterone acetate(E2V+ MPA) sequential therapy, 26 women took estradiol valerate and Progesterone Soft Capsules(E2V+ P) sequential therapy, 30 women took Kuntai capsule, and 27 took Cohosh extract...
August 2, 2016: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Fatemeh Seyyedi, Mahmoud Rafiean-Kopaei, Sepideh Miraj
INTRODUCTION: Several causes can disturb the quality of life in postmenopausal women. Stress, urinary incontinence is one of the factors that can influence the quality of life of women, since they evade social activities and limit their behavior. Vulvovaginal disorders adversely impacts sexual action, psychosocial health, and partner relationships. AIM: The aim of this study was to examine the therapeutic properties of vaginal cream of royal jelly and estrogen on quality of life, sexual and urinary problems in postmenopausal women...
May 2016: Journal of Clinical and Diagnostic Research: JCDR
Risa Kagan, Barry S Komm, Kelly A Ryan, Joanne Lavenberg, Ching-Ray Yu, JoAnn V Pinkerton
OBJECTIVE: The aim of the study was to determine the time course of effect with conjugated estrogens/bazedoxifene (CE/BZA) in nonhysterectomized postmenopausal women in five phase 3 trials. METHODS: This post hoc analysis identified when CE 0.45 mg/BZA 20 mg and CE 0.625 mg/BZA 20 mg first achieved a statistically significant difference (P < 0.05) versus placebo in individual trials and the duration the difference persisted for prespecified efficacy endpoints...
July 18, 2016: Menopause: the Journal of the North American Menopause Society
R Hurtado, M Celani, S Geber
OBJECTIVE: To evaluate the effect of short-term hormone replacement therapy with 0.625 mg conjugated estrogens daily on endothelial function of healthy postmenopausal women, using flow-mediated dilation (FMD) of the brachial artery. METHODS: We performed a double-blinded, randomized, controlled trial over 3 years. Randomization was performed using computer-generated sorting. All participants were blinded to the use of conjugated equine estrogens (CEE) or placebo and FMD was assessed by a blinded examiner, before and after 28 days of medication...
October 2016: Climacteric: the Journal of the International Menopause Society
J Christopher Gallagher, Santiago Palacios, Kelly A Ryan, Ching-Ray Yu, Kaijie Pan, David L Kendler, Sebastian Mirkin, Barry S Komm
OBJECTIVE: Conjugated estrogens/bazedoxifene reduces vasomotor symptoms and prevents postmenopausal bone loss without stimulating the breast and endometrium. We analyzed changes in bone mineral density (BMD) and bone markers using pooled data from two phase-3 trials. METHODS: Selective Estrogens, Menopause, and Response to Therapy (SMART)-1 and SMART-5 were randomized, double-blind, placebo- and active-controlled studies conducted in postmenopausal nonhysterectomized women...
October 2016: Menopause: the Journal of the North American Menopause Society
JoAnn V Pinkerton, Lucy Abraham, Andrew G Bushmakin, Joseph C Cappelleri, Barry S Komm
OBJECTIVE: This study characterizes and quantifies the relationship of vasomotor symptoms (VMS) of menopause with menopause-specific quality of life (MSQOL) and sleep parameters to help predict treatment outcomes and inform treatment decision-making. METHODS: Data were derived from a 12-week randomized, double-blind, placebo-controlled phase 3 trial that evaluated effects of two doses of conjugated estrogens/bazedoxifene on VMS in nonhysterectomized postmenopausal women (N = 318, mean age = 53...
October 2016: Menopause: the Journal of the North American Menopause Society
JoAnn V Pinkerton, Andrew G Bushmakin, Lucy Abraham, Joseph C Cappelleri, Barry S Komm
OBJECTIVE: Conjugated estrogens/bazedoxifene (CE/BZA) is indicated to treat moderate/severe menopausal vasomotor symptoms and prevent postmenopausal osteoporosis. This analysis examines the impact of the most bothersome vaginal symptom at baseline on effects of CE/BZA. METHODS: This post hoc analysis used data from a 12-week clinical trial of nonhysterectomized postmenopausal women (n = 664) randomly assigned to double-blind treatment with CE/BZA (0.45/20 mg and 0...
October 2016: Menopause: the Journal of the North American Menopause Society
Ajaz Ahmad, Sujan Kumar Mondal, Basit Latief Jan, Debabrata Mukhopadhyay, Rajkumar Banerjee, Khalid M Alkharfy
A lipid-conjugated, estrogenic derivative molecule (ESC8) that, in compare to other estrogenic molecules encouraged cell death in both ER-positive and ER-negative breast cancer cells. A rapid and highly sensitive assay method has been developed and validated for the estimation of a ESC8 in rat plasma using liquid chromatography coupled with mass spectrometry under a positive-ion mode with electrospray ionization. The sample process includes using methanol for precipitation of ESC8 and dextromethorphan (internal standard, IS) from plasma...
June 16, 2016: Biomedical Chromatography: BMC
Richard J Santen, Yan Song, Ji-Ping Wang, Wei Yue
The first tissue-selective estrogen complex (TSEC), consisting of a combination of a conjugated equine estrogen (CEE) and bazedoxifene (BZA), has been approved for treatment of the menopause in the USA and European Union. We have postulated that this TSEC might block the estrogenic effects of CEE on breast tissue and thereby prevent breast cancer growth. This manuscript, representing a presentation at a Festschrift honoring Evan Simpson, reviews our published data BZA blocked the in vitro effects of both estradiol and CEE on cell growth and gene expression in MCF-7 cells...
May 9, 2016: Journal of Steroid Biochemistry and Molecular Biology
Chi-Yan Tsai, Chun-Wei Li, Jie-Ren Li, Bo-Han Jang, Shu-Hui Chen
Steroid ligands can easily diffuse through the cell membrane and this property makes it feasible to be used for in-situ staining of the nuclear receptors. However, nonspecific binding of the internalized ligand probe with the cellular components has caused serious interferences for the detection of receptor-expressing cells. We report a novel gold nanocluster (AuNC)-conjugated estrogen probe that can eliminate nonspecific internalization and accelerate nuclear localization to achieve selective and rapid detection of estrogen receptors (ERs) in live cells...
July 2016: Journal of Fluorescence
JoAnn V Pinkerton, James H Pickar, Kelly A Ryan, Ching-Ray Yu, Sebastian Mirkin, Barry S Komm
OBJECTIVE: The aim of the study was to compare efficacy of conjugated estrogens (CE)/bazedoxifene (BZA) for treatment of menopausal symptoms and prevention of postmenopausal osteoporosis in minorities (black/Hispanic) versus whites. METHODS: In a post hoc analysis, data were pooled from 3,424 white or minority nonhysterectomized postmenopausal women randomized to CE 0.45 or 0.625 mg/BZA 20 mg or placebo in four double-blind, phase 3 Selective Estrogens, Menopause, and Response to Therapy (SMART) trials...
June 2016: Menopause: the Journal of the North American Menopause Society
Risa Kagan, Steven R Goldstein, James H Pickar, Barry S Komm
Menopausal symptoms (eg, hot flushes and vaginal symptoms) are common, often bothersome, and can adversely impact women's sexual functioning, relationships, and quality of life. Estrogen-progestin therapy was previously considered the standard care for hormone therapy (HT) for managing these symptoms in nonhysterectomized women, but has a number of safety and tolerability concerns (eg, breast cancer, stroke, pulmonary embolism, breast pain/tenderness, and vaginal bleeding) and its use has declined dramatically in the past decade since the release of the Women's Health Initiative trial results...
2016: Therapeutics and Clinical Risk Management
Ning Jie Yang, Dong-Won Seol, Junghyun Jo, Hyun Mee Jang, Sook-Young Yoon, Woo Sik Lee, Dong Ryul Lee
Estrogen-related receptor β (ESRRB), which is a member of the nuclear orphan receptor family, regulates the messenger RNA (mRNA) expression levels of the transcription factors,Oct4andNanog, in early embryos and germ cells, thereby maintaining the undifferentiated state and pluripotency of the relevant cells. The present study was designed to determine whether the upregulation of pluripotency-related genes by direct delivery of ESRRB protein may affect on the commitment into inner cell mass (ICM) or the development of vitrified/warmed mouse embryos...
April 12, 2016: Reproductive Sciences
Li Ma, Scott R Yates, Daniel Ashworth
This present study investigated the occurrence of 13 parent and conjugated estrogens and progestagens in surface water of the Santa Ana River. With the exception of the synthetic hormones 17 α-ethynylestradiol and mestranol, other compounds were detected at least twice at 10 representative sites, with the ubiquitous estrone (E1) and 17β-estradiol-3-sulfate as the dominant compounds quantified (0.24-6.37 ng/L and 0.49-9.25 ng/L, respectively). Sites near dairy farms exhibited high levels of conjugates while those close to a sewage treatment plant (STP) effluent outlet displayed relatively high concentrations of E1...
April 6, 2016: Environmental Toxicology and Chemistry
Sebastian Mirkin, JoAnn V Pinkerton, Risa Kagan, John R Thompson, Kaijie Pan, James H Pickar, Barry S Komm, David F Archer
OBJECTIVE: To evaluate gynecologic safety of conjugated estrogens/bazedoxifene treatment for menopausal symptoms and osteoporosis prevention in nonhysterectomized women. MATERIALS AND METHODS: We pooled data from five randomized, placebo-controlled trials of conjugated estrogens 0.625 mg/bazedoxifene 20 mg (n = 1583), conjugated estrogens 0.45 mg/bazedoxifene 20 mg (n = 1585), and placebo (n = 1241). Gynecologic safety was evaluated by pelvic examination, Papanicolaou smear, endometrial biopsy, transvaginal ultrasound, mammogram, adverse events, and diary records of vaginal bleeding and breast pain/tenderness...
May 2016: Journal of Women's Health
S Palacios, L Arias, J Lavenberg, K Pan, S Mirkin, B S Komm
Introduction Conjugated estrogens/bazedoxifene (CE/BZA) relieves menopausal symptoms and increases bone mineral density (BMD). Objective To evaluate CE/BZA in a Latin American subpopulation from randomized, double-blind, phase-3, multinational trials. Methods Safety data were pooled from three trials from non-hysterectomized postmenopausal Latin American women assigned to CE 0.45 mg/BZA 20 mg (n = 227), CE 0.625 mg/BZA 20 mg (n = 222), or placebo (n = 193). Efficacy outcomes from one study included changes in hot flush frequency at week 12 in women with at least seven moderate/severe hot flushes/day or 50/week at baseline (n = 39), and from baseline to month 12 for BMD (n = 381) and genitourinary syndrome of menopause (GSM) (women with baseline GSM; n = 189)...
June 2016: Climacteric: the Journal of the International Menopause Society
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"